The Medical Letter on Drugs and Therapeutics
Brodalumab (Siliq) - Another IL-17A Antagonist for Psoriasis
The full article is available to subscribers Subscriber Login   

The FDA has approved brodalumab (Siliq – Valeant), an injectable human interleukin (IL)-17A receptor antagonist, for treatment of adults with moderate to severe plaque psoriasis who have failed to respond to other systemic therapies. Brodalumab is the third IL-17A antagonist to be approved in the US for this indication; secukinumab (Cosentyx) and ixekizumab (Taltz) were approved earlier.1,2

STANDARD TREATMENT — Plaque psoriasis is a chronic, inflammatory, immune-mediated skin condition. Mild to moderate psoriasis is generally treated with topical corticosteroids. Topical vitamin D analogs and the retinoid tazarotene (Tazorac, and others) are alternatives that can be used alone or in combination with topical corticosteroids.3 For patients with moderate to severe disease, systemic options include ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Brodalumab (Siliq) - Another IL-17A Antagonist for Psoriasis
Article code: 1525b
 Electronic, downloadable article - $25